Last reviewed · How we verify
NCT05899491
Role of ARMA in Selective Subset of Refractory GERD Patients.
NA trial testing ARMA in GERD in 50 participants. Completed in 30 December 2023.
30 September 2023
Quick facts
| Lead sponsor | Asian Institute of Gastroenterology, India |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 30 March 2023 |
| Primary completion | 30 September 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across India |
Drugs / interventions tested
- ARMA
- UGI Endoscopy
Conditions studied
- GERD — all drugs for GERD →
- Reflux — all drugs for Reflux →
- Reflux Esophagitis — all drugs for Reflux Esophagitis →
Sponsor
Asian Institute of Gastroenterology, India
Who can join
19 and older, any sex, with GERD or Reflux. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the role of a novel endoscopic treatment technique (ARMA) in GERD patients who doesn't respond to PPI therapy (Proton Pump Inhibitor).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05899491
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for GERD
Currently open trials in the same condition.
- NCT06953986 — A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA · NA · recruiting
- NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
- NCT07268820 — Heartburn, Gastroesophageal Reflux Disease · Phase 4 · recruiting
- NCT06955520 — Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM · NA · recruiting
- NCT06641375 — Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: · NA · recruiting
Other Asian Institute of Gastroenterology, India trials
Trials by the same sponsor.
- NCT07486518 — A Multicentre Prospective Cohort Study of The Gastric Precancerous Epithelial Pathway Using High-Definition Endoscopy An · not yet recruiting
- NCT07413822 — A Single-centre Open, Prospective, Pilot Clinical Study to Assess the Safety and Performance of the TIES® Transcutaneous · NA · not yet recruiting
- NCT07399652 — Artificial Intelligence-Guided Detection of Blood Vessels to Enhance Safety in Third-Space Endoscopic Procedures · NA · recruiting
- NCT07371832 — A Single Center Evaluation of AI Enabled SureForm Robotic Stapler (SureformTM) Compared to Conventional Stapler for Colo · recruiting
- NCT07329816 — External, Multicentre Validation of a Machine-Learning Model to Predict Colonic Adenoma in Indian Adults · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05899491 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asian Institute of Gastroenterology, India
- Last refreshed: 4 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05899491.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing